FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody binding to CLDN6. Also disclosed are: a method of inhibiting cell growth, a method of destroying a cell, a method of treating or preventing a disease or disorder, a method of inhibiting metastatic spread of cells – using said antibody. Disclosed is a conjugate comprising said antibody, a pharmaceutical composition comprising said antibody.
EFFECT: invention effectively treats diseases associated with CLDN6.
30 cl, 43 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
